Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 2
2019 1
2020 1
2021 3
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Feagan BG, et al. Among authors: besuyen r. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. Lancet. 2021. PMID: 34090625 Clinical Trial.
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
Reinisch W, Hellstrom W, Dolhain RJEM, Sikka S, Westhovens R, Mehta R, Ritter T, Seidler U, Golovchenko O, Simanenkov V, Garmish O, Jeka S, Moravcová R, Rajendran V, Le Brun FO, Arterburn S, Watkins TR, Besuyen R, Vanderschueren D. Reinisch W, et al. Among authors: besuyen r. Ann Rheum Dis. 2023 Aug;82(8):1049-1058. doi: 10.1136/ard-2023-224017. Epub 2023 May 3. Ann Rheum Dis. 2023. PMID: 37137672 Free PMC article. Clinical Trial.
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Maksymowych WP, Østergaard M, Landewé R, Barchuk W, Liu K, Tasset C, Gilles L, Hendrikx T, Besuyen R, Baraliakos X. Maksymowych WP, et al. Among authors: besuyen r. Rheumatology (Oxford). 2022 May 5;61(5):2063-2071. doi: 10.1093/rheumatology/keab543. Rheumatology (Oxford). 2022. PMID: 34352069 Free PMC article. Clinical Trial.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, Matzkies F, Genovese MC, Jiang D, Chen K, Bartok B, Jahreis A, Besuyen R, Burmester GR, Gottenberg JE. Winthrop KL, et al. Among authors: besuyen r. Ann Rheum Dis. 2022 Feb;81(2):184-192. doi: 10.1136/annrheumdis-2021-221051. Epub 2021 Nov 5. Ann Rheum Dis. 2022. PMID: 34740884 Free PMC article.
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Kavanaugh A, et al. Among authors: besuyen r. J Rheumatol. 2021 Aug;48(8):1230-1238. doi: 10.3899/jrheum.201183. Epub 2021 Feb 1. J Rheumatol. 2021. PMID: 33526618 Free article. Clinical Trial.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Ishiguro N, Tanaka Y, Matsubara T, Atsumi T, Amano K, Sugiyama E, Yamaoka K, Winthrop K, Kivitz A, Burmester GR, Gottenberg JE, Genovese MC, Matzkies F, Guo Y, Jiang D, Bartok B, Pechonkina A, Kondo A, Besuyen R, Takeuchi T. Ishiguro N, et al. Among authors: besuyen r. Mod Rheumatol. 2023 Jan 3;33(1):64-72. doi: 10.1093/mr/roac020. Mod Rheumatol. 2023. PMID: 35365828
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M. Hibi T, et al. Among authors: besuyen r. Intest Res. 2023 Jan;21(1):110-125. doi: 10.5217/ir.2021.00143. Epub 2022 Mar 11. Intest Res. 2023. PMID: 35263963 Free PMC article.
16 results